Horizon 2020 Calls for Proposals:
To view all of the available Horizon 2020 funding, please proceed to the European Union Research Participant Portal.
Horizon Prize - Better use of Antibiotics
Feb 25, 2015 23:00PM
Pillar: Societal Challenges
Type: Call for Proposals
Planned Opening Date: Tue, 10 Mar 2015
Deadline: Wed, 17 Aug 2016 17:00:00 (Brussels local time)
Budget: 1.000.000,00 €
Depending on the overall requirements and the available Management budget, ERIO is able to offer a range of advice, support and project management services from the negotiation stages until a project's closure, including:
- Negotiation and administration of the Grant Agreement
- Drafting, negotiation and administration of the Consortium Agreement
- Project monitoring and reporting throughout the project's life cycle
- Facilitation of communications, including the setup and maintenance of collaboration software, project websites and the organisation of project meetings and reviews
- Management of Intellectual Property and confidentiality considerations
- Contractual management, including the maintenance of the various agreements and the drafting of sub-contracts and competitive calls
Following discussions with the European Commission and a successful pilot, ERIO may also (in some cases and where appropriate) be in a position to offer management support and consultancy services to EU funded projects in which UCL is not the project's Coordinator.
This work can be costed into your project's Management budget category, and by bringing ERIO (via UCL) into your project as a managing partner a considerable portion of the administrative burden of EU project management can be removed from the coordinating scientists.
For further details please contact Michael Browne, Head of European Research and Innovation. Tel: +44 (0)20 3108 3120 Email: email@example.com
Below is a small selection of the projects currently being managed by the European Research and Innovation Office's European Project Managers.
'CHAIN' - Collaborative HIV and Anti-HIV Drug Resistance Network
- Call: FP7 Health 2007 (Large Scale Integrating Project)
PI and Coordinator: Prof. Deenan Pillay, Research Department of Infection
- Total Budget: €13.15 million (UCL EC contribution: €1.4 million)
- Duration: April 2009 to March 2014
- Oveview: CHAIN is a large scale integrating project designed to effectively and durably combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and heavily affected resource-poor regions in Africa. This will be achieved through the consortium’s pan-European network of surveillance and basic research activities, the involvement of all main actors in the field of HIV and anti-HIV drug resistance, monitoring how resistances develop and evolve, improved understanding of mechanisms of resistance development, performing molecular epidemiology studies, providing improved and new strategies to evaluate and limit the emergence and transmission of HIV drug resistance, setting up training and dissemination activities and supporting evidence-based public health policy and action.
'VPH NoE' - Virtual Physiological Human Network of Excellence
- Call: FP7 ICT 2007 (Network of Excellence)
Coordinator: Prof. Peter Coveney, Department of Chemistry
Budget: €9.65 million (UCL EC contribution: €1.3 million)
- Duration: June 2008 to November 2012
- Oveview: The aims of this project range from the development of a VPH ToolKit and associated infrastructural resources through integration of models and data across the various relevant levels of physiological structure and functional organisation, to VPH community building and support. The VPH NoE aims to foster the development of new and sustainable educational, training and career structures for those involved in VPH related science, technology and medicine, and will lay the foundations for a future Virtual Physiological Human Institute.
'Antiresdev' - The effects of antibiotic administration on the emergence and persistence of antibiotic-resistant bacteria in humans and on the composition of the indifenous microbiotas at various body sites
- Call: FP7 Health 2009 (Small or Medium-scale focused research project)
- PI and Coordinator: Prof. Mike Wilson, Eastman Centre for Microbial Infections
Total Budget: €7.08 million (UCL EC contribution: €882,060)
- Duration: November 2009 to October 2012
- Oveview: ANTIRESDEV is studying the impact of different antibiotics on the prevalence of resistant bacteria in the human host. The project is using culture-based and culture-independent approaches to investigate the impact of four types of antibiotics on the emergence of antibiotic-resistant organisms and their persistence at several body sites. Disruption of the indigenous microbiota is an important factor in the persistence and transmission of antibiotic-resistant organisms, therefore this project also focuses on the ecological impact of the antibiotics on the indigenous microbiotas of several body sites using culture-dependent and -independent techniques. The project also involves the identification of the genes responsible for resistance in the antibiotic-resistant organisms isolated, using state-of-the-art micro-arrays.
'EuroCoord' - European network of HIV/AIDS cohort studies to coordinate at European and International level clinical research on HIV/AIDS
- Call: FP7 Health 2010 (Network of Excellence)
Coordinator: Dr. Kholoud Porter, Medical Research Council
Budget: €15.97 million (UCL EC contribution: €2.17 million)
- Duration: January 2011 to December 2015
- Oveview: Over the past 15 years, EU-funded cohorts and collaborations (EuroSIDA,
CASCADE, COHERE and PENTA) have played a central role in developing our
understanding of HIV progression and the effects of ART, enabling
European expertise to contribute directly to the advances in patient
diagnosis and management worldwide, and providing a continued
surveillance mechanism for detection of emerging problems at a European
level. Together, these
collaborations form the foundation of a Network of Excellence named EuroCoord. EuroCoord currently has access to data from over 250,000 HIV-infected individuals
across the European continent and beyond, will address key areas of HIV research aimed at improving the
management and life of HIV-infected individuals, whilst
exploring differences within sub-groups.